Skip to main content
TISSUE REPAIR LTD logo

TISSUE REPAIR LTD — Investor Relations & Filings

Ticker · TRP ISIN · AU0000180887 ASX Professional, scientific and technical activities
Open in API
Filings indexed 139 across all filing types
Latest filing 2024-02-29 Board/Management Inform…
Country AU Australia
Listing ASX TRP

About TISSUE REPAIR LTD

https://tissuerepair.com.au/

Tissue Repair Ltd is a clinical-stage biopharmaceutical company focused on the development of advanced wound healing and skin repair agents. The company’s core technology centers on Glucoprime, a proprietary yeast-derived beta-glucan designed to stimulate the innate immune system and accelerate the body's natural healing processes. Its lead candidate, TR-987, is being developed for the treatment of chronic wounds, such as venous leg ulcers, and for use in post-procedural recovery following aesthetic treatments. By targeting the inflammatory phase of wound healing, the technology aims to improve clinical outcomes and reduce recovery times. The company focuses on addressing unmet needs in both the medical wound care and cosmetic dermatology markets through its specialized biological platform.

Recent filings

Filing Released Lang Actions
Change of Company Secretary 1 page 176.1KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement dated 1 March 2024 regarding a change in the company secretary of Tissue Repair Limited. It references compliance with ASX Listing Rules and provides contact information for further inquiries. There is no financial data, no mention of financial results, no detailed report content, and the document is relatively short (1685 characters). It is an announcement about a management change, specifically the appointment and resignation of company secretaries. This fits the category of Board/Management Information (MANG).
2024-02-29 English
Appendix 4D and Half Year Report to 31 December 2023 18 pages 570.9KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Tissue Repair Ltd Appendix 4D Half-year report' and covers the half-year ended 31 December 2023. It includes detailed financial statements such as consolidated statement of profit or loss, financial position, cash flows, notes to the financial statements, directors' report, and auditor's review report. The presence of comprehensive financial data and analysis for a half-year period indicates this is a substantive interim financial report. The document is about 15,000 characters long, which is consistent with a full interim report rather than a brief announcement or certification. The document also references the auditor's review report as part of the half-year financial report, confirming it is the actual report and not just an announcement. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2024-02-28 English
Quarterly Activities/Appendix 4C Cash Flow Report 9 pages 416.7KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 30 January 2024, providing a quarterly update on the company's progress and attaching its Appendix 4C Quarterly Cashflow Report for the period ended 31 December 2023. The text includes detailed operational updates, financial summaries, and a consolidated statement of cash flows for the quarter and year to date. The Appendix 4C is a standard quarterly cash flow report required by the ASX Listing Rules 4.7B, which is a regulatory filing for entities listed on the ASX. The document contains substantive financial data and analysis for the quarter, not merely an announcement of a report or a certification. Therefore, this document is best classified as an Interim / Quarterly Report (IR).
2024-01-29 English
Third US Patent granted for Tissue Repair Glucoprime 2 pages 199.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 19 December 2023, detailing the granting of a third US patent for Tissue Repair's Glucoprime® technology. It discusses patent numbers, claims, and the commercial implications of the patents. There is no financial data, no mention of quarterly or annual results, no management discussion of financial performance, and no regulatory certifications or officer attestations. The document is a corporate announcement about intellectual property developments and commercial strategy related to patents. It does not fit into financial report categories like Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or Management Reports (MDA). It is not a regulatory filing or certification. It is also not related to capital raising, share transactions, or governance changes. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous corporate announcements that do not fit other categories.
2023-12-18 English
Application for quotation of securities - TRP 6 pages 27.3KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX, specifically regarding restricted securities where the escrow period has expired or is about to expire. It details the number and type of securities to be quoted, issue dates, and the status of issued capital following quotation. There is no financial performance data, management discussion, or audit information. The document is an official announcement related to capital structure changes, specifically the listing or quotation of shares. This fits the category of Share Issue/Capital Change (SHA). The document length and content confirm it is not a brief announcement but a detailed application for quotation, supporting a confident classification.
2023-11-19 English
Change of Director's Interest Notice - Michael Silberberg 2 pages 280.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a change in a director's relevant interests in securities, specifically the acquisition of unlisted options by a director. The document includes specifics such as the director's name, date of change, number and class of securities acquired, and nature of the change. This matches the definition of a Director's Dealing report, which involves reporting personal share transactions by company directors and executives. The document length is 3420 characters, which is consistent with a detailed notice rather than a brief announcement or a full report. Therefore, the correct classification is Director's Dealing (DIRS).
2023-11-15 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.